Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia

EMBO Molecular Medicine

Volumn 5, Issue 9, 2013, Pages 1351-1366

  Park, Jung Eun ^a   Yuen, Hiu Fung ^a   Zhou, Jian Biao ^b   Al aidaroos, Abdul Qader O ^a   Guo, Ke ^a   Valk, Peter J ^c   Zhang, Shu Dong ^d   Chng, Wee Joo ^b,e,f   Hong, Cheng William ^g   Mills, Ken ^d   Zeng, Qi ^a,h  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e National University Cancer Institute   (Singapore)

^f Dept Medicine Endocrinol Diabet   (Singapore)

^g CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Acute myeloid leukaemia; Antibody therapy; FLT3 ITD mutation; PRL 3; Prognostic marker

Indexed keywords

CD135 ANTIGEN; FLT3 LIGAND; JANUS KINASE; MESSENGER RNA; PROLACTIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ACUTE MYELOID LEUKAEMIA; ANTIBODY THERAPY; FLT3-ITD MUTATION; PRL-3; PROGNOSTIC MARKER;

CELL LINE, TUMOR; CELL PROLIFERATION; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS; PROTEIN TYROSINE PHOSPHATASES;

EID: 84883311476     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201202183     Document Type: Article

References (58)

1. Al-Aidaroos AQ, Zeng Q (2010) PRL-3 phosphatase and cancer metastasis. J Cell Biochem 111: 1087-1098
2. Balasubramanian S, Eckert RL (2007) Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes. J Biol Chem 282: 6707-6715
3. Baldus CD, Bullinger L (2008) Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia. Semin Oncol 35: 356-364
4. Bessette DC, Qiu D, Pallen CJ (2008) PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 27: 231-252
5. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, Courtneidge SA (2000) SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20: 9018-9027
6. Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, et al (2013) Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 5: 176ra133
7. Eferl R, Wagner EF (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868
8. Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, et al (2008) Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood 111: 806-815
9. Ferrone S (2011) Hidden immunotherapy targets challenge dogma. Sci Transl Med 3: 99ps38
10. Fiordalisi JJ, Keller PJ, Cox AD (2006) PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res 66: 3153-3161
11. Gaidzik V, Dohner K (2008) Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 35: 346-355
12. Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, Varghese L, Huang C, Zeng Q (2011) Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 3: 99ra85
13. Guo K, Li J, Wang H, Osato M, Tang JP, Quah SY, Gan BQ, Zeng Q (2006) PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res 66: 9625-9635
14. Guo K, Tang JP, Jie L, Al-Aidaroos AQ, Hong CW, Tan CP, Park JE, Varghese L, Feng Z, Zhou J, et al (2012) Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget 3: 158-171
15. Guo K, Tang JP, Tan CP, Wang H, Zeng Q (2008) Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther 7: 750-757
16. Hebestreit K, Gröttrup S, Emden D, Veerkamp J, Ruckert C, Klein H.-U, Müller-Tidow C, Dugas M (2012) Leukemia Gene atlas - a public platform for integrative exploration of genome-wide molecular data. PLoS One 7: e39148
17. Hong CW, Zeng Q (2012) Awaiting a new era of cancer immunotherapy. Cancer Res 72: 3715-3719
18. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, Wagner EF (2007) p38[alpha] suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39: 741-749
19. Hwang JJ, Min SH, Sin KH, Heo YS, Kim KD, Yoo OJ, Lee SH (2011) Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer. Oncol Rep 27: 535-540
20. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105: 1759-1767
21. Kohlmann A, Bullinger L, Thiede C, Schaich M, Schnittger S, Dohner K, Dugas M, Klein HU, Dohner H, Ehninger G, et al (2010) Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 24: 1216-1220
22. Levis M, Small D (2003) FLT3: ITDoes matter in leukemia. Leukemia 17: 1738-1752
23. Li J, Guo K, Koh VWC, Tang JP, Gan BQ, Shi H, Li HX, Zeng Q (2005) Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases. Clin Cancer Res 11: 2195-2204
24. Li Y, Li H, Wang M-N, Lu D, Bassi R, Wu Y, Zhang H, Balderes P, Ludwig DL, Pytowski B, et al (2004) Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood 104: 1137-1144
25. Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY (2007) PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 282: 5413-5419
26. Lin KR, Lee SF, Hung CM, Li CL, Yang-Yen HF, Yen JJ (2007) Survival factor withdrawal-induced apoptosis of TF-1 cells involves a TRB2-Mcl-1 axis-dependent pathway. J Biol Chem 282: 21962-21972
27. Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341: 1051-1062
28. Matsukawa Y, Semba S, Kato H, Koma Y, Yanagihara K, Yokozaki H (2010) Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo. Pathobiology 77: 155-162
29. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, et al (2008) An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112: 4193-4201
30. Ming J, Liu N, Gu Y, Qiu X, Wang EH (2009) PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer. Pathology 41: 118-126
31. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, Gruning W, Kratz-Albers K, Serve S, Steur C, et al (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96: 3907-3914
32. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911-1918
33. Nam J-S, Ino Y, Sakamoto M, Hirohashi S (2002) Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 8: 2430-2436
34. Odgerel T, Kikuchi J, Wada T, Shimizu R, Futaki K, Kano Y, Furukawa Y (2007) The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. Oncogene 27: 3102-3110
35. Peng L, Xing X, Li W, Qu L, Meng L, Lian S, Jiang B, Wu J, Shou C (2009) PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling. Mol Cancer 8: 110
36. Pulikkan JA, Dengler V, Peer Zada AA, Kawasaki A, Geletu M, Pasalic Z, Bohlander SK, Ryo A, Tenen DG, Behre G (2010) Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML. Leukemia 24: 914-923
37. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG (2003) FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17: 120-124
38. Rangatia J, Vangala RK, Singh SM, Peer Zada AA, Elsasser A, Kohlmann A, Haferlach T, Tenen DG, Hiddemann W, Behre G (2003) Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction. Oncogene 22: 4760-4764
39. Ren T, Jiang B, Xing X, Dong B, Peng L, Meng L, Xu H, Shou C (2009) Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer. Pathol Oncol Res 15: 555-560
40. Robinson LJ, Xue J, Corey SJ (2005) Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 33: 469-479
41. Rockova V, Abbas S, Wouters BJ, Erpelinck CAJ, Beverloo HB, Delwel R, van Putten WLJ, Löwenberg B, Valk PJM (2011) Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 118: 1069-1076
42. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, et al (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294: 1343-1346
43. Seidel HM, Milocco LH, Lamb P, Darnell JE, Stein RB, Rosen J (1995) Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci 92: 3041-3045
44. Small D (2006) FLT3 mutations: biology and treatment. Hematology 2006: 178-184
45. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103: 3669-3676
46. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W (2003) Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 9: 2140-2150
47. Sternberg DW, Licht JD (2005) Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Curr Opin Hematol 12: 7-13
48. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, et al (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628
49. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Lowenberg B, Delwel R, Valk PJ (2009) Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94: 131-134
50. Wang L, Shen Y, Song R, Sun Y, Xu J, Xu Q (2009) An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol 76: 1238-1245
51. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD (2009) FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 12: 81-89
52. Weisberg E, Sattler M, Ray A, Griffin JD (2010) Drug resistance in mutant FLT3-positive AML. Oncogene 29: 5120-5134
53. Wiernik PH (2010) FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 8: 429-436, 444
54. Wingender E, Dietze P, Karas H, Knüppel R (1996) TRANSFAC: a database on transcription factors and their DNA binding sites. Nucleic Acids Res 24: 238-241
55. Zeng Q, Hong W, Tan YH (1998) Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun 244: 421-427
56. Zhang W, Liu HT (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12: 9-18
57. Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, Yuan G, Zhang H, Yu M, Hu M, Shen B, Guo N (2007) Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer 7: 145
58. Zhou J, Bi C, Chng W, Cheong L, Liu S, Mahara S, Tay K, Zeng Q, Li J, Guo K, et al (2011) PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS ONE 6: e19798